With the free-fall in dot com stocks, money has flowed--with a vengeance--into biotech. But the valuations are not sustainable: most of the new companies are shooting for a market far too small to support even half of the new competitors, and trying to sell only portions of what drug companies want to buy.
You may also be interested in...
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.
The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.
GSK launches a 100% natural saline spray in the UK to compliment its Piri hayfever brand portfolio.